Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes

Journal of Immunotherapy

Volumn 32, Issue 7, 2009, Pages 726-736

  Kaka, Anjum S ^a,b   Shaffer, Donald R ^a   Hartmeier, Ryan ^a   Leen, Ann M ^a,b   Lu, An ^a   Bear, Adham ^a   Rooney, Cliona M ^a,b   Foster, Aaron E ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; CTL; IL 21; T antigen presenting cell

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HERMES ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7 RECEPTOR ALPHA; L SELECTIN; LENTIVIRUS VECTOR; LEUKEMIA ANTIGEN; LYMPHOID ENHANCER FACTOR 1; MELAN A; MELANOMA ANTIGEN; RNA; TRANSCRIPTION FACTOR 7;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL EXPANSION; CELL PROLIFERATION; CELL SPECIFICITY; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DNA MODIFICATION; GENE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERLEUKIN 21 GENE; MEMORY T LYMPHOCYTE; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE ANTIGEN PRESENTING CELL;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERLEUKINS; K562 CELLS; LENTIVIRUS; LYMPHOID ENHANCER-BINDING FACTOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T CELL TRANSCRIPTION FACTOR 1; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 68449096174     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ad4071     Document Type: Article

References (45)

1. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838-2845.
2. Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113:2442-2450.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
4. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000; 192: 1637-1644.
5. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-373.
6. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
7. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25:243-251.
8. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
9. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
10. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
11. Huang J, Khong HT, Dudley ME, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28:258-267.
12. Powell DJ Jr, Dudley ME, Robbins PF, et al. Transition of late-stage effector T cells to CD27 + CD28 + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005; 105:241-250.
13. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells. J Clin Invest. 2005;115:1616-1626.
14. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102:9571-9576.
15. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742-751.
16. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
17. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol. 2002;2:982-987.
18. Appay V, Dunbar PR, Callan M, et al. Memory CD8 + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
19. Ochsenbein AF, Riddell SR, Brown M, et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med. 2004;200:1407-1417.
20. Xiang J, Huang H, Liu Y. A new dynamic model of CD8 + T effector cell responses via CD4 + T helper-antigen-presenting cells. J Immunol. 2005;174:7497-7505.
21. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175:7046-7052.
22. Kaech SM, Tan JT, Wherry EJ, et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191-1198.
23. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63.
24. Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immunol Rev. 2004;202:84-95.
25. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol. 2007;178:2827-2834.
26. Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8 + T cells for adoptive immunotherapy. Blood. 2008;111:5326-5333.
27. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175:2261-2269.
28. Ansen S, Butler MO, Berezovskaya A, et al. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res. 2008;14:6125-6136.
29. Brandt K, Bulfone-Paus S, Foster DC, et al. Interleukin-21 inhibits dendritic cell activation and maturation. Blood. 2003; 102:4090-4098.
30. Foster AE, Leen AM, Lee T, et al. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007;30:506-516.
31. Cooper LJ, Al Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105:1622-1631.
32. Fontana R, Bregni M, Cipponi A, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood. 2009;113:1651-1660.
33. Giannopoulos K, Li L, Bojarska-Junak A, et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol. 2006;29:95-103.
34. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101:1905-1912.
35. Tong-Starkesen SE, Luciw PA, Peterlin BM. Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat. J Immunol. 1989;142:702-707.
36. Dumais N, Pare ME, Mercier S, et al. T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of human T-cell leukemia virus type 1. J Virol. 2003;77:11170-11179.
37. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
38. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003; 300:337-339.
39. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8 + memory T cells. Nature. 2006;441:890-893.
40. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
41. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science. 2000;290:92-97.
42. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 2009;106:3360-3365.
43. Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8 + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol. 2004; 173:900-909.
44. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4 + T lymphocytes. J Immunol. 2007;178:732-739.
45. Kim-Schulze S, Kim HS, Fan Q, et al. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2009;17:380-388.